News ESMO26: Tango sees 82% ORR with combo in pancreatic cancer A study of RevMed's Rasonque with Tango's vopimetostat has raised hopes of a new combination therapy for aggressive pancreatic cancer.
News RevMed nears EU okay for pancreatic cancer drug Rasonque Revolution Medicines is just weeks away from getting EU approval for its keenly anticipated oral RAS drug Rasonque for pancreatic cancer.
News Revolution's ASCO showstopper gets FDA greenlight The RAS inhibitor for pancreatic cancer that received a standing ovation at ASCO for its doubling of overall survival now has its FDA approval.
News ASCO26: Revolution's 'grand slam' data in pancreatic cancer Revolution Medicines' pan-RAS(on) inhibitor daraxonrasib has delivered an unprecedented result in pancreatic cancer.
News Late-breakers to look out for at ASCO 2026 ASCO is just around the corner, and there is the usual fertile crop of high-profile trials to look out for among the late-breaker presentations.
News Revolution rockets on strong pancreatic cancer data Revolution Medicines thinks it could transform the treatment of pancreatic cancer based on phase 3 data with its pan-RAS(on) inhibitor daraxonrasib.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.